Janux Therapeutics (JANX) Insider Trading & Ownership $22.76 -1.24 (-5.17%) Closing price 04:00 PM EasternExtended Trading$23.10 +0.34 (+1.49%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Janux Therapeutics (NASDAQ:JANX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.10%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$67.59MNumber OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$6.62M Get JANX Insider Trade Alerts Want to know when executives and insiders are buying or selling Janux Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JANX Insider Buying and Selling by Quarter Janux Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/1/2025Andrew Hollman MeyerInsiderSell3,333$32.03$106,755.99 4/21/2025Andrew Hollman MeyerInsiderSell3,334$30.00$100,020.00 3/7/2025Ra Capital Management, L.P.DirectorBuy110,206$31.02$3,418,590.12 3/5/2025Ra Capital Management, L.P.DirectorBuy341,742$30.64$10,470,974.88 3/3/2025Andrew Hollman MeyerInsiderSell3,334$32.15$107,188.10 2/3/2025Andrew Hollman MeyerInsiderSell3,334$42.29$140,994.86 1/7/2025David Alan CampbellCEOSell5,000$60.00$300,000.00 1/2/2025Andrew Hollman MeyerInsiderSell13,334$54.88$731,769.92 12/24/2024David Alan CampbellCEOSell25,000$56.19$1,404,750.00 12/3/2024David Alan CampbellCEOSell15,000$67.00$1,005,000.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 11/25/2024David Alan CampbellCEOSell25,000$51.60$1,290,000.00 10/28/2024David Alan CampbellCEOSell25,000$53.54$1,338,500.00 10/18/2024Ra Capital Management, L.P.DirectorBuy1,200,000$44.75$53,700,000.00 10/17/2024Ventures Xi L.P. AvalonMajor ShareholderSell1,843$50.02$92,186.86 (Data available from 1/1/2013 forward) JANX Insider Trading Activity - Frequently Asked Questions Who is on Janux Therapeutics' Insider Roster? The list of insiders at Janux Therapeutics includes Andrew Hollman Meyer, David Alan Campbell, Jay Lichter, Ra Capital Management, L.P., Tighe Reardon, and Ventures Xi L.P. Avalon. Learn more on insiders at JANX. What percentage of Janux Therapeutics stock is owned by insiders? 8.10% of Janux Therapeutics stock is owned by insiders. Learn more on JANX's insider holdings. Which Janux Therapeutics insiders have been buying company stock? The following insiders have purchased JANX shares in the last 24 months: Ra Capital Management, L.P. ($67,589,565.00), and Ventures Xi L.P. Avalon ($4,988,642.98). How much insider buying is happening at Janux Therapeutics? Insiders have purchased a total of 2,501,802 JANX shares in the last 24 months for a total of $72,578,207.98 bought. Which Janux Therapeutics insiders have been selling company stock? The following insiders have sold JANX shares in the last 24 months: Andrew Hollman Meyer ($3,484,728.87), David Alan Campbell ($6,496,000.00), Jay Lichter ($82,125,000.00), Tighe Reardon ($45,043,974.75), and Ventures Xi L.P. Avalon ($51,575,441.04). How much insider selling is happening at Janux Therapeutics? Insiders have sold a total of 3,517,279 Janux Therapeutics shares in the last 24 months for a total of $188,725,144.66 sold. Janux Therapeutics Key ExecutivesDr. David Alan Campbell Ph.D. (Age 64)President, CEO & Director Compensation: $1.04MMr. Charles M. Winter (Age 55)Chief Technical Officer Compensation: $590.4kMr. Byron Robinson J.D. (Age 59)Ph.D., Chief Strategy Officer Compensation: $723kMr. Tighe M. Reardon C.F.A. (Age 48)CPA, Acting Chief Financial Officer Dr. Tommy Diraimondo Ph.D. (Age 38)Chief Scientific Officer Mr. James PenningtonGeneral CounselMs. Brenda Van VreeswykHead of Human ResourcesMr. Andy Hollman Meyer (Age 40)Chief Business Officer 2 recent trades More Insider Trading Tools from MarketBeat Related Companies MRUS Insider Buying KRYS Insider Buying PTCT Insider Buying ARWR Insider Buying ACLX Insider Buying PCVX Insider Buying CRNX Insider Buying PTGX Insider Buying KYMR Insider Buying MLTX Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Marvell Insiders Buy Shares—Should Investors Follow Suit?Insider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t WorryTop Insider Buys and Sells From September: Buy, Sell, or Hold?NuScale, Rocket Lab Face Heavy Insider Selling After Surges This page (NASDAQ:JANX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
